What BMI do you need for Zepbound under BCBS Wyoming?

For weight loss on Employer / Commercial Insurance plans, BCBS Wyoming requires a BMI of 30 or higher, or 27 or higher with a qualifying weight-related condition. Other plan types may differ — see each plan type below.

How long does a Zepbound approval last with BCBS Wyoming?

Initial approvals last 12 months, and renewals are granted in 12-month periods.

What does BCBS Wyoming require to renew Zepbound?

At least 5% weight loss from the starting weight, For renewal (after 52 weeks on maximum-tolerated dose), patient must have achieved and maintained >= 5% weight loss from baseline. Patients with = 85th percentile for age and sex, not combining with another weight loss agent, maintaining low-calorie diet/increased physical activity/behavioral modifications, not combining with another GLP-1 agonist, and no FDA labeled contraindications, and at least 52 weeks on therapy before the first renewal.

How current is this information?

This page reflects BCBS Wyoming's written policy as of June 1, 2026, last verified against the source document on June 4, 2026.

BCBS Wyoming

Does BCBS Wyoming cover Zepbound?

Quick answer · Weight Loss

BCBS Wyoming covers Zepbound for weight loss with prior authorization on Employer / Commercial Insurance and ACA Marketplace.

Employer / Commercial Insurance: Covered with requirements. BMI of 30 or higher
ACA Marketplace: Covered with requirements. BMI of 30 or higher

Last verified June 4, 2026. Policy effective June 1, 2026. Source: WY_Weight_Management_PAQL_ProgSum.pdf. How we verify this data →

Check your card for your exact plan →

Zepbound for Weight Loss

What BCBS Wyoming requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

Age 12 and older
BMI of 30 or higher
BMI of 27 or higher with a weight-related condition (hypertension, T2DM, OSA, CVD, and dyslipidemia)
BMI of 25 or higher for patients of Asian descent
BMI at or above the 95th percentile for age and sex
6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Adult weight management (BMI >= 30)

All of:

Patient is an adult (18 years of age or over)
BMI >= 30 kg/m^2
Obesity is NOT restricted from coverage under the patient's benefit
Patient is new to therapy, new to Prime, or attempting a repeat weight loss course of therapy
Patient has been on a weight loss regimen of low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
Patient will NOT use the requested agent in combination with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications to the requested agent
Patient is currently on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications AND will continue it
Age is within FDA labeling for the requested indication OR there is support for use at patient's age

Plus any one of:

Patient has NOT tried a targeted weight loss agent (e.g., Saxenda, Wegovy, Zepbound) in the past 12 months
Patient tried a targeted weight loss agent for a previous course of therapy in the past 12 months AND prescriber anticipates success with repeating therapy

Adult weight management (BMI >= 25 - Asian descent)

All of:

Patient is an adult (18 years of age or over)
Patient is of South Asian, Southeast Asian, or East Asian descent
BMI >= 25 kg/m^2
Obesity is NOT restricted from coverage under the patient's benefit
Patient is new to therapy, new to Prime, or attempting a repeat weight loss course of therapy
Patient has been on a weight loss regimen of low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
Patient will NOT use the requested agent in combination with another weight loss agent
Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications to the requested agent
Patient is currently on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications AND will continue it
Age is within FDA labeling for the requested indication OR there is support for use at patient's age

Plus any one of:

Patient has NOT tried a targeted weight loss agent in the past 12 months
Patient tried a targeted weight loss agent for a previous course of therapy in the past 12 months AND prescriber anticipates success with repeating therapy

Adult weight management (BMI >= 27 with comorbidity)

All of:

Patient is an adult (18 years of age or over)
BMI >= 27 kg/m^2
At least one weight-related comorbidity/risk factor/complication (e.g., hypertension, type 2 diabetes mellitus, obstructive sleep apnea, cardiovascular disease, dyslipidemia)
Obesity is NOT restricted from coverage under the patient's benefit
Patient is new to therapy, new to Prime, or attempting a repeat weight loss course of therapy
Patient has been on a weight loss regimen of low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
Patient will NOT use the requested agent in combination with another weight loss agent
Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications to the requested agent
Patient is currently on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications AND will continue it
Age is within FDA labeling for the requested indication OR there is support for use at patient's age

Plus any one of:

Patient has NOT tried a targeted weight loss agent in the past 12 months
Patient tried a targeted weight loss agent for a previous course of therapy in the past 12 months AND prescriber anticipates success with repeating therapy

Pediatric weight management (age 12-17)

All of:

Patient is pediatric (12 to 17 years of age)
Obesity is NOT restricted from coverage under the patient's benefit
Patient is new to therapy, new to Prime, or attempting a repeat weight loss course of therapy
Patient has been on a weight loss regimen of low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
Patient will NOT use the requested agent in combination with another weight loss agent
Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications to the requested agent
Patient is currently on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications AND will continue it
Age is within FDA labeling for the requested indication OR there is support for use at patient's age

Plus any one of:

BMI >= 95th percentile for age and sex
BMI >= 30 kg/m^2
BMI >= 85th percentile for age and sex AND at least one weight-related comorbidity/risk factor/complication (e.g., hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea)

Documentation to bring

Documentation of BMI >= 30 kg/m^2 (or >= 27 with comorbidity, or >= 25 if Asian descent, or BMI percentile for pediatric patients)
Documentation of 6-month weight loss regimen (low-calorie diet, increased physical activity, behavioral modifications)
Documentation of weight-related comorbidity if using the 27 kg/m^2 threshold
Documentation of ancestry if using the 25 kg/m^2 Asian threshold
Documentation that obesity is not restricted from coverage under the patient's benefit

Quantity limits

2.5 MG/0.5 ML vial — 4 Vials per 180 days (84-day)
5 MG/0.5 ML vial, 7.5 MG/0.5 ML vial, 10 MG/0.5 ML vial, 12.5 MG/0.5 ML vial, 15 MG/0.5 ML vial — 4 Vials per 28 days
2.5 MG/0.5 ML autoinjector — 4 Pens per 180 days (84-day)
5 MG/0.5 ML autoinjector, 7.5 MG/0.5 ML autoinjector, 10 MG/0.5 ML autoinjector, 12.5 MG/0.5 ML autoinjector, 15 MG/0.5 ML autoinjector — 4 Pens per 28 days
2.5 MG/0.6 ML KwikPen — 1 Pen per 180 days (84-day)
5 MG/0.6 ML KwikPen, 7.5 MG/0.6 ML KwikPen, 10 MG/0.6 ML KwikPen, 12.5 MG/0.6 ML KwikPen, 15 MG/0.6 ML KwikPen — 1 Pen per 28 days

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for at least 5% weight loss from the starting weight, For renewal (after 52 weeks on maximum-tolerated dose), patient must have achieved and maintained >= 5% weight loss from baseline. Patients with < 52 weeks on maximum-tolerated dose may also qualify without demonstrating weight loss. Renewal also requires: obesity not restricted from benefit, continuing current weight loss course of therapy, pediatric patients (12-17) must have current BMI >= 85th percentile for age and sex, not combining with another weight loss agent, maintaining low-calorie diet/increased physical activity/behavioral modifications, not combining with another GLP-1 agonist, and no FDA labeled contraindications, and at least 52 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

Combination with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical) not allowed
Combination with another GLP-1 receptor agonist (e.g., Saxenda, Wegovy, Zepbound, Bydureon, Byetta, Mounjaro, Ozempic, Rybelsus, Trulicity, Victoza) not allowed
Any FDA labeled contraindications to the requested agent
Obesity restricted from coverage under the patient's benefit

Policy note: Zepbound available as vials, autoinjectors, and KwikPens — all covered. For continuation after 52 weeks on maximum-tolerated dose, patient must demonstrate >= 5% weight loss from baseline. Patients with < 52 weeks on maximum-tolerated dose may qualify for renewal without demonstrating weight loss. Policy also allows approval if patient has another FDA labeled indication for the requested agent. This weight_loss entry excludes the OSA pathway, which is captured separately.

Policy effective June 1, 2026 · verified June 4, 2026 · source: WY_Weight_Management_PAQL_ProgSum.pdf

ACA Marketplace

Covered with requirements

What you need to qualify

Age 12 and older
BMI of 30 or higher
BMI of 27 or higher with a weight-related condition (hypertension, T2DM, OSA, CVD, and dyslipidemia)
BMI of 25 or higher for patients of Asian descent
BMI at or above the 95th percentile for age and sex
6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Adult weight management (BMI >= 30)

All of:

Patient is an adult (18 years of age or over)
BMI >= 30 kg/m^2
Obesity is NOT restricted from coverage under the patient's benefit
Patient is new to therapy, new to Prime, or attempting a repeat weight loss course of therapy
Patient has been on a weight loss regimen of low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
Patient will NOT use the requested agent in combination with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications to the requested agent
Patient is currently on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications AND will continue it
Age is within FDA labeling for the requested indication OR there is support for use at patient's age

Plus any one of:

Patient has NOT tried a targeted weight loss agent (e.g., Saxenda, Wegovy, Zepbound) in the past 12 months
Patient tried a targeted weight loss agent for a previous course of therapy in the past 12 months AND prescriber anticipates success with repeating therapy

Adult weight management (BMI >= 25 - Asian descent)

All of:

Patient is an adult (18 years of age or over)
Patient is of South Asian, Southeast Asian, or East Asian descent
BMI >= 25 kg/m^2
Obesity is NOT restricted from coverage under the patient's benefit
Patient is new to therapy, new to Prime, or attempting a repeat weight loss course of therapy
Patient has been on a weight loss regimen of low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
Patient will NOT use the requested agent in combination with another weight loss agent
Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications to the requested agent
Patient is currently on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications AND will continue it
Age is within FDA labeling for the requested indication OR there is support for use at patient's age

Plus any one of:

Patient has NOT tried a targeted weight loss agent in the past 12 months
Patient tried a targeted weight loss agent for a previous course of therapy in the past 12 months AND prescriber anticipates success with repeating therapy

Adult weight management (BMI >= 27 with comorbidity)

All of:

Patient is an adult (18 years of age or over)
BMI >= 27 kg/m^2
At least one weight-related comorbidity/risk factor/complication (e.g., hypertension, type 2 diabetes mellitus, obstructive sleep apnea, cardiovascular disease, dyslipidemia)
Obesity is NOT restricted from coverage under the patient's benefit
Patient is new to therapy, new to Prime, or attempting a repeat weight loss course of therapy
Patient has been on a weight loss regimen of low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
Patient will NOT use the requested agent in combination with another weight loss agent
Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications to the requested agent
Patient is currently on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications AND will continue it
Age is within FDA labeling for the requested indication OR there is support for use at patient's age

Plus any one of:

Patient has NOT tried a targeted weight loss agent in the past 12 months
Patient tried a targeted weight loss agent for a previous course of therapy in the past 12 months AND prescriber anticipates success with repeating therapy

Pediatric weight management (age 12-17)

All of:

Patient is pediatric (12 to 17 years of age)
Obesity is NOT restricted from coverage under the patient's benefit
Patient is new to therapy, new to Prime, or attempting a repeat weight loss course of therapy
Patient has been on a weight loss regimen of low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
Patient will NOT use the requested agent in combination with another weight loss agent
Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications to the requested agent
Patient is currently on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications AND will continue it
Age is within FDA labeling for the requested indication OR there is support for use at patient's age

Plus any one of:

BMI >= 95th percentile for age and sex
BMI >= 30 kg/m^2
BMI >= 85th percentile for age and sex AND at least one weight-related comorbidity/risk factor/complication (e.g., hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea)

Documentation to bring

Documentation of BMI >= 30 kg/m^2 (or >= 27 with comorbidity, or >= 25 if Asian descent, or BMI percentile for pediatric patients)
Documentation of 6-month weight loss regimen (low-calorie diet, increased physical activity, behavioral modifications)
Documentation of weight-related comorbidity if using the 27 kg/m^2 threshold
Documentation of ancestry if using the 25 kg/m^2 Asian threshold
Documentation that obesity is not restricted from coverage under the patient's benefit

Quantity limits

2.5 MG/0.5 ML vial — 4 Vials per 180 days (84-day)
5 MG/0.5 ML vial, 7.5 MG/0.5 ML vial, 10 MG/0.5 ML vial, 12.5 MG/0.5 ML vial, 15 MG/0.5 ML vial — 4 Vials per 28 days
2.5 MG/0.5 ML autoinjector — 4 Pens per 180 days (84-day)
5 MG/0.5 ML autoinjector, 7.5 MG/0.5 ML autoinjector, 10 MG/0.5 ML autoinjector, 12.5 MG/0.5 ML autoinjector, 15 MG/0.5 ML autoinjector — 4 Pens per 28 days
2.5 MG/0.6 ML KwikPen — 1 Pen per 180 days (84-day)
5 MG/0.6 ML KwikPen, 7.5 MG/0.6 ML KwikPen, 10 MG/0.6 ML KwikPen, 12.5 MG/0.6 ML KwikPen, 15 MG/0.6 ML KwikPen — 1 Pen per 28 days

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for at least 5% weight loss from the starting weight, For renewal (after 52 weeks on maximum-tolerated dose), patient must have achieved and maintained >= 5% weight loss from baseline. Patients with < 52 weeks on maximum-tolerated dose may also qualify without demonstrating weight loss. Renewal also requires: obesity not restricted from benefit, continuing current weight loss course of therapy, pediatric patients (12-17) must have current BMI >= 85th percentile for age and sex, not combining with another weight loss agent, maintaining low-calorie diet/increased physical activity/behavioral modifications, not combining with another GLP-1 agonist, and no FDA labeled contraindications, and at least 52 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

Combination with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical) not allowed
Combination with another GLP-1 receptor agonist (e.g., Saxenda, Wegovy, Zepbound, Bydureon, Byetta, Mounjaro, Ozempic, Rybelsus, Trulicity, Victoza) not allowed
Any FDA labeled contraindications to the requested agent
Obesity restricted from coverage under the patient's benefit

Policy effective June 1, 2026 · verified June 4, 2026 · source: WY_Weight_Management_PAQL_ProgSum.pdf

Zepbound for Osa

What BCBS Wyoming requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

BMI of 30 or higher
Prescribed by or in consultation with a specialist
Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

OSA - Initial Approval (Zepbound only)

All of:

Diagnosis of obstructive sleep apnea (OSA)
Polysomnography (PSG) or home sleep apnea test performed
AHI >= 15 events/hour from baseline (prior to initiation of pharmacotherapy)
Requested agent is Zepbound
BMI >= 30 kg/m^2
Patient does NOT have craniofacial abnormalities that may affect breathing
Patient does NOT have diagnosis of Central or Mixed Sleep Apnea with mixed or central apneas/hypopneas >= 50%
Patient does NOT have diagnosis of Cheyne Stokes Respiration
Patient does NOT have diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia
Prescriber is a specialist (e.g., pulmonologist, sleep specialist) or has consulted with a specialist

Documentation to bring

Medical records confirming diagnosis of obstructive sleep apnea (OSA)
Polysomnography (PSG) or home sleep apnea test results showing AHI >= 15 events/hour at baseline
Documentation of BMI >= 30 kg/m^2
Documentation that patient does NOT have craniofacial abnormalities affecting breathing
Documentation that patient does NOT have Central or Mixed Sleep Apnea with >= 50% mixed or central apneas/hypopneas
Documentation that patient does NOT have Cheyne Stokes Respiration
Documentation that patient does NOT have Obesity Hypoventilation Syndrome or daytime hypercapnia
Documentation of specialist prescriber or specialist consultation (e.g., pulmonologist, sleep specialist)

Quantity limits

2.5 MG/0.5 ML vial — 4 Vials per 180 days (84-day)
5 MG/0.5 ML vial, 7.5 MG/0.5 ML vial, 10 MG/0.5 ML vial, 12.5 MG/0.5 ML vial, 15 MG/0.5 ML vial — 4 Vials per 28 days
2.5 MG/0.5 ML autoinjector — 4 Pens per 180 days (84-day)
5 MG/0.5 ML autoinjector, 7.5 MG/0.5 ML autoinjector, 10 MG/0.5 ML autoinjector, 12.5 MG/0.5 ML autoinjector, 15 MG/0.5 ML autoinjector — 4 Pens per 28 days
2.5 MG/0.6 ML KwikPen — 1 Pen per 180 days (84-day)
5 MG/0.6 ML KwikPen, 7.5 MG/0.6 ML KwikPen, 10 MG/0.6 ML KwikPen, 12.5 MG/0.6 ML KwikPen, 15 MG/0.6 ML KwikPen — 1 Pen per 28 days

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for Patient must demonstrate clinical benefit with the requested agent (e.g., reduction in AHI, decrease in Epworth Sleepiness Scale). AHI baseline measurement and PSG/home sleep test are NOT re-required at renewal. Specialist/consultation requirement remains.

Not covered when

Craniofacial abnormalities that may affect breathing
Central or Mixed Sleep Apnea with mixed or central apneas/hypopneas >= 50%
Cheyne Stokes Respiration
Obesity Hypoventilation Syndrome or daytime hypercapnia
Any FDA labeled contraindications to the requested agent

Policy note: Policy does NOT require prior PAP/CPAP therapy trial for OSA indication. AHI threshold is >= 15 events/hour (moderate-to-severe OSA). At renewal, clinical benefit is required (e.g., reduction in AHI, decrease in Epworth Sleepiness Scale) but repeat PSG/home sleep test is not explicitly required. Specialist (e.g., pulmonologist, sleep specialist) or specialist consultation required at both initial and renewal.

Policy effective June 1, 2026 · verified June 4, 2026 · source: WY_Weight_Management_PAQL_ProgSum.pdf

ACA Marketplace

Covered with requirements

What you need to qualify

BMI of 30 or higher
Prescribed by or in consultation with a specialist
Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

OSA - Initial Approval (Zepbound only)

All of:

Diagnosis of obstructive sleep apnea (OSA)
Polysomnography (PSG) or home sleep apnea test performed
AHI >= 15 events/hour from baseline (prior to initiation of pharmacotherapy)
Requested agent is Zepbound
BMI >= 30 kg/m^2
Patient does NOT have craniofacial abnormalities that may affect breathing
Patient does NOT have diagnosis of Central or Mixed Sleep Apnea with mixed or central apneas/hypopneas >= 50%
Patient does NOT have diagnosis of Cheyne Stokes Respiration
Patient does NOT have diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia
Prescriber is a specialist (e.g., pulmonologist, sleep specialist) or has consulted with a specialist

Documentation to bring

Medical records confirming diagnosis of obstructive sleep apnea (OSA)
Polysomnography (PSG) or home sleep apnea test results showing AHI >= 15 events/hour at baseline
Documentation of BMI >= 30 kg/m^2
Documentation that patient does NOT have craniofacial abnormalities affecting breathing
Documentation that patient does NOT have Central or Mixed Sleep Apnea with >= 50% mixed or central apneas/hypopneas
Documentation that patient does NOT have Cheyne Stokes Respiration
Documentation that patient does NOT have Obesity Hypoventilation Syndrome or daytime hypercapnia
Documentation of specialist prescriber or specialist consultation (e.g., pulmonologist, sleep specialist)

Quantity limits

2.5 MG/0.5 ML vial — 4 Vials per 180 days (84-day)
5 MG/0.5 ML vial, 7.5 MG/0.5 ML vial, 10 MG/0.5 ML vial, 12.5 MG/0.5 ML vial, 15 MG/0.5 ML vial — 4 Vials per 28 days
2.5 MG/0.5 ML autoinjector — 4 Pens per 180 days (84-day)
5 MG/0.5 ML autoinjector, 7.5 MG/0.5 ML autoinjector, 10 MG/0.5 ML autoinjector, 12.5 MG/0.5 ML autoinjector, 15 MG/0.5 ML autoinjector — 4 Pens per 28 days
2.5 MG/0.6 ML KwikPen — 1 Pen per 180 days (84-day)
5 MG/0.6 ML KwikPen, 7.5 MG/0.6 ML KwikPen, 10 MG/0.6 ML KwikPen, 12.5 MG/0.6 ML KwikPen, 15 MG/0.6 ML KwikPen — 1 Pen per 28 days

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for Patient must demonstrate clinical benefit with the requested agent (e.g., reduction in AHI, decrease in Epworth Sleepiness Scale). AHI baseline measurement and PSG/home sleep test are NOT re-required at renewal. Specialist/consultation requirement remains.

Not covered when

Craniofacial abnormalities that may affect breathing
Central or Mixed Sleep Apnea with mixed or central apneas/hypopneas >= 50%
Cheyne Stokes Respiration
Obesity Hypoventilation Syndrome or daytime hypercapnia
Any FDA labeled contraindications to the requested agent

Policy effective June 1, 2026 · verified June 4, 2026 · source: WY_Weight_Management_PAQL_ProgSum.pdf

Why Zepbound requests get denied by BCBS Wyoming

Based on what this policy asks for. Fix these before the first submission.

Wrong brand for the diagnosis. Zepbound and Mounjaro are the same molecule with different approved uses; a request for Zepbound under a diagnosis that matches Mounjaro is routinely denied.
BMI not documented in the chart notes (or documented without a baseline weight and date).
Qualifying weight-related condition not documented with its own diagnosis code.
No documented diet and exercise program.
Prescriber isn't the specialist the plan requires.
Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

Frequently asked questions

Does BCBS Wyoming cover Zepbound?: BCBS Wyoming covers Zepbound for weight loss with prior authorization on Employer / Commercial Insurance and ACA Marketplace.
What BMI do you need for Zepbound under BCBS Wyoming?: For weight loss on Employer / Commercial Insurance plans, BCBS Wyoming requires a BMI of 30 or higher, or 27 or higher with a qualifying weight-related condition. Other plan types may differ — see each plan type below.
How long does a Zepbound approval last with BCBS Wyoming?: Initial approvals last 12 months, and renewals are granted in 12-month periods.
What does BCBS Wyoming require to renew Zepbound?: At least 5% weight loss from the starting weight, For renewal (after 52 weeks on maximum-tolerated dose), patient must have achieved and maintained >= 5% weight loss from baseline. Patients with < 52 weeks on maximum-tolerated dose may also qualify without demonstrating weight loss. Renewal also requires: obesity not restricted from benefit, continuing current weight loss course of therapy, pediatric patients (12-17) must have current BMI >= 85th percentile for age and sex, not combining with another weight loss agent, maintaining low-calorie diet/increased physical activity/behavioral modifications, not combining with another GLP-1 agonist, and no FDA labeled contraindications, and at least 52 weeks on therapy before the first renewal.
How current is this information?: This page reflects BCBS Wyoming's written policy as of June 1, 2026, last verified against the source document on June 4, 2026.

Other medications under BCBS Wyoming

Zepbound coverage under other plans

All insurance plans · All medications

This page summarizes BCBS Wyoming's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.